Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Bad Day for Lucentis

This article was originally published in RPM Report

Executive Summary

On July 21, Roche reported strong first half sales of Lucentis. It was all downhill from there.
Advertisement

Related Content

Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond
Eylea Pricing is Eye-Opening: Regeneron Plays to CMS, Payors on Price; Docs with Terms
Biopharma's Default Position: Drug Stocks Hold Up Against US Downgrade
The New Ophthalmic Drug Players
Reacting to the CATT Study: Will Makena Make a Difference?
Cut to the Bone: Amgen Faces Further Aranesp Decline Ahead of Denosumab
Access and Evidence: Implications of the EPO Safety Debate (Part 2)
Living in a Bipolar World: Implications of the EPO Safety Debate (Part 1)
An Eye for an Eye: Lucentis and the New Pharmaceutical Value System

Topics

Advertisement
UsernamePublicRestriction

Register

PS080860

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel